Systagenix to present new Woundchek evidence at EWMA 2012

Systagenix is presenting new evidence that underlines the clinical benefits delivered by its Woundchek Protease Status system this week.

The company is attending the European Wound Management Association (EWMA) 2012 conference to showcase study data that illustrates the importance of protease activity in wound healing and wound assessment.

It is estimated that elevated protease activity (EPA) is associated with a 90 percent probability of a wound not healing without appropriate intervention, while 28 percent of non-healing wounds are thought to have EPA.

This underlines the potential benefits offered by Systagenix's Woundchek device, the only commercially available device in Europe that can detect EPA.

Dr Rob Snyder, Systagenix's medical director, said: "Early detection and treatment of EPA will be vital to improving healing rates and preventing recalcitrance that could cost billions. Ultimately, this could result in forestalling disability and pain affecting thousands of patients."

Earlier this month, the company revealed that more than 1,000 clinicians have been trained to use the WoundChek Protease Status since its launch.